Soleno Therapeutics Receives Breakthrough Therapy Designation From FDA For DCCR Extended-Release Tablets in Prader-Willi Syndrome

-0.04%

Soleno Therapeutics Inc

SLNO

45.18

-0.04%

First Ever Breakthrough Designation for a Drug Being Developed for PWS

Designation is Based on Data from the Phase 3 Program for DCCR

Planned Submission of a New Drug Application (NDA) for DCCR Remains on Track for Mid-2024

More This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.